- Operating income: 27.20 billion yen, up 96% year-over-year (YoY), beat estimate of 24.7 billion yen.
- Net income: 17.89 billion yen, up 87% YoY, beat estimate of 16.95 billion yen.
- Net sales: 449.47 billion yen, up 10% YoY, beat estimate of 429.78 billion yen.
2025 Year Forecast:
- Operating income forecast: 113.00 billion yen, close to estimate of 114.38 billion yen.
- Net income forecast: 73.00 billion yen, close to estimate of 74.73 billion yen.
- Net sales forecast: 1.85 trillion yen, in line with estimate of 1.84 trillion yen.
- Dividend forecast: 150.00 yen, near estimate of 150.83 yen.
- Shares rose 9.6% to 3,862 yen with 754,800 shares traded.
- Analysts’ recommendations: 12 buys, 2 holds, 1 sell.
Comparisons are based on the company’s original disclosures.
A look at Mitsui Chemicals Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Mitsui Chemicals shows a solid performance in terms of value and dividends, scoring 4 and 5 respectively. This indicates a favorable outlook for investors looking for stable returns and income generation. Despite a slightly lower score in growth and resilience at 3 and 2, the company still holds promise for long-term potential.
With a momentum score of 3, Mitsui Chemicals displays a moderate trend in market performance. Considering its diverse product range in ethylene, propylene, petrochemicals, and fine chemicals, coupled with a global presence, the company appears well-positioned to navigate market challenges. Investors seeking a balanced investment opportunity may find Mitsui Chemicals a favorable choice for their portfolio.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
